Development and acceptability of a shared decision-making tool for commercial peanut allergy therapies
Matthew Greenhawt(University of Michigan), Daniel D. Matlock, Tonya Winders, Edwin Kim(University of North Carolina at Chapel Hill), Don A. Bukstein(Institute for Asthma and Allergy), John Oppenheimer(Rutgers, The State University of New Jersey), Marcus Shaker(Dartmouth College), David R. Stukus(The Ohio State University), Edmond S. Chan(University of British Columbia), Ray S. Davis(Washington University in St. Louis), David M. Fleischer(Children's Hospital Colorado)
Cited by 52
Related Papers
Decision Making in Advanced Heart Failure
|Circulation|2012|810
Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis
|Journal of Allergy and Clinical Immunology|2020|690
International consensus guidelines for the diagnosis and management of food protein–induced enterocolitis syndrome: Executive summary—Workgroup Report of the Adverse Reactions to Foods Committee, American Academy of Allergy, Asthma & Immunology
|Journal of Allergy and Clinical Immunology|2017|675
Drug allergy: A 2022 practice parameter update
|Journal of Allergy and Clinical Immunology|2022|533
Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel
|Journal of Allergy and Clinical Immunology|2017|502